|
Albert Graham,
Backyard Pool Drainer
|
Since breast cancer is now being detected at an earlier stage than previously and since adjuvant chemotherapy may cause ovarian failure, an increasing number of women are becoming postmenopausal at a younger age after breast cancer treatment.
Fifty-two chemotherapy naive patients with metastatic breast cancer entered into the study and were treated with vinorelbine 25 mg/m2 plus doxorubicin 25 mg/m2 both on days 1 and 8 every three weeks.
This pilot experience indicates that the majority of breast cancer patients respond normally to the stresses of both adjuvant and palliative chemotherapy; quality of life does not appear to improve three to eight months after termination of chemotherapy; family support is good in the majority of cases and that subset of patients with severe anxiety who could benefit from pharmacological and/or psychological intervention can be identified.
|
|
Zhang Xian Qian,
Ex-Olympic Swimmer
|
CONCLUSIONS: Combination chemotherapy with Doxil and vinorelbine affords treatment with two active drugs in women with metastatic breast cancer, and appears to have a favorable toxicity profile.
|
|
Arthur Dawkins,
Astro-physicist
|
This paper critically examines the literature related to the impact of adjuvant chemotherapy and reproductive hormone changes on cognitive function in women with breast cancer and suggests direction for future research in this area.
This study investigates the efficacy and toxicity of docetaxel in metastatic breast cancer patients with previous chemotherapy for metastatic disease.
Now breast cancer is likely to result in a lumpectomy or a modified mastectomy, and combined with modern chemotherapy and radiation therapy, survival rates are dramatically increased.
|
|
Thomas Owens,
Police Officer
|
Breast cancer activist Rose Kushner wrote that by 1981 "indiscriminate, automatic adjuvant chemotherapy was replacing the Halsted radical mastectomy as therapeutic overkill in the United States.
|
|
David Rosenberg,
Dermatologist
|
A study that demonstrated that an intensive bone marrow transplant regimen for patients with metastatic breast cancer who responded to inital standard chemotherapy did not improve time to disease progression or lifetime survival.
ELLENCE is the first chemotherapy approved by the FDA for use as a component of adjuvant therapy, in combination with cyclophosphamide and fluorouracil (CEF), in the treatment of early-stage breast cancer that has spread to the lymph nodes.
Chemotherapy treatment for patients with early breast cancer that has spread to lymph nodes.
|
|
Bob Greenberg,
Congressional Candidate
|
Wound complications in patients receiving adjuvant chemotherapy after mastectomy and immediate breast reconstruction for breast cancer.
|
|
|
